Montana Healthcare Programs
Physician-Administered Drug Coverage Criteria

SPINRAZA® (nusinersen)

I. Medication Description
Spinraza® is a survival motor neuron-2 (SMN-2)-directed antisense oligonucleotide indicated for:
- Treatment of spinal muscular atrophy (SMA) in pediatric and adult patients

II. Position Statement
Coverage is determined through a prior authorization process that must include supporting clinical documentation for each request.

III. Initial Coverage Criteria
Member must meet all the following criteria:
- Member must have a diagnosis of Spinal Muscular Atrophy Type 1, 2 or 3 (SMA1, SMA2 or SMA3) confirmed by genetic testing.
- Genetic testing has confirmed chromosome 5q homozygous deletions or dysfunctional point mutations of the SMN1 gene and two to <four copies of SMN2 gene.
- Member must not have permanent ventilator dependence.
- Spinraza® is prescribed by a neurologist.
- Prescriber must submit documentation of a baseline motor function milestone evaluation using at least one of the following age-appropriate screening tools:
  - HINE-2 (Hammersmith Infant Neurological Exam Part 2) – Appropriate for children two to 24 months of age
  - CHOP-INTEND (Children’s Hospital of Philadelphia Infant Test of Neuromuscular Diseases) – Appropriate for infants, children and older people with an infant’s repertoire of motor skills
  - HFMSE (Hammersmith Functional Motor Scale Expanded) – Appropriate for individuals over 24 months of age with later-onset SMA (Type 2 or Type 3)
  - RULM (Revised Upper Limb Module Test) – Appropriate for assessing upper limb function of ambulatory and non-ambulatory individuals
  - 6MWT (6 Minute Walking Test) – Appropriate for ambulatory patients with later-onset SMA (Type 2 or Type 3)
- Provider attests the following laboratory tests will be performed at baseline and prior to each administration of Spinraza®: platelet count, coagulation test, quantitative spot urine protein test.
- Member has not previously received Zolgensma®, or member has previously received Zolgensma® and has experienced a worsening in clinical status.
- Member is not concurrently using Evrysdi™.
IV. Renewal Coverage Criteria
Member must meet all the following criteria:
- Member has been adherent to Spinraza®.
- Member has experienced a positive clinical response, as demonstrated by improvement or maintenance of motor skills as compared to pre-treatment baseline using at least one of the following age appropriate screening tools:
  - HINE-2 (Hammersmith Infant Neurological Exam Part 2) – Appropriate for children two to 24 months of age
  - CHOP-INTEND (Children’s Hospital of Philadelphia Infant Test of Neuromuscular Diseases) – Appropriate for infants, children and older people with an infant’s repertoire of motor skills
  - HFMSE (Hammersmith Functional Motor Scale Expanded) – Appropriate for individuals over 24 months of age with later-onset SMA (Type 2 or Type 3)
  - RULM (Revised Upper Limb Module Test) – Appropriate for assessing upper limb function of ambulatory and non-ambulatory individuals
  - 6MWT (6 Minute Walking Test) – Appropriate for ambulatory patients with later-onset SMA (Type 2 or Type 3)
- Provider attests the following laboratory tests are being performed prior to each administration of Spinraza®: platelet count, coagulation test and quantitative spot urine test.
- Member has not received Zolgensma®, or member has previously received Zolgensma® and has experienced a worsening in clinical status.
- Member is not concurrently using Evrysdi™.

V. Quantity Limitations
Max of 12mg/dose intrathecally, as follows:
- The first three loading doses should be administered at 14-day intervals. The fourth loading dose should be administered 30 days after the third dose.
- A maintenance dose should be administered once every four months thereafter.

VI. Coverage Duration
Initial approval duration: 6 months (total of first 4 loading doses and 1 maintenance dose)
Renewal approval duration: 1 year